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In recent years, alternative and complementary medicine including the plant-based drugs with antioxidant and neuroptotective 
effects has attracted a growing interest. Resveratrol, a polyphenolic compound which is found in various plant species, has emerged 
as a promising nutraceutical with therapeutic potentials in neuropsychiatric, cardiometabolic and cancer diseases, also aging. 
encouraging potential to treat or prevent chronic and age-related disorders has raised a considerable number of clinical trials. 
Recently, resveratrol is implicated the biology of nerve growth factor (NGF), a critical player in the maintenance of neuronal 
growth and function. Furthermore, resveratrol affects the endocannabinoid signalling (eCBs) which exerts modulatory effects 
in the survival signalling pathways, neural plasticity, and
therapeutic effects of this ubiquitous signalling system in Alzheimer’s disease, epilepsy, multiple sclerosis, mood and movement 
disorders, spinal cord injury, and stroke have been well-documented. In the present review, the implication of NGF and eCBs in 
the mechanism of action of resveratrol, that may be
is highlighted. Biomed Rev 2015; 26: 13-21.
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INTRODUCTION 
herbs have shown the ability of plants to synthesize a variety 
of compounds which interact with biological pathways (1). 
trans-stilbene; C14H12O3, 
Fig. 1), a polyphenolic compound which is found in various 
plant species, has shown a wide range of pharmacological 
activities. This phytochemical (nutraceutical) inhibits the 
cytokines leading to the antiinflammatory and analgesic 
effects (2). Resveratrol via the induction of apoptosis of 
cancer cells and metabolism of carcinogens as well as 
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inhibition of cancer initiation and progression signalling 
a well-characterized target of cancers (4), inhibition of this 
signalling pathway by resveratrol (2) may be implicated 
in the anticarcinogenic effects of this natural polyphenol. 
Regarding the cardiometabolic protection, resveratrol 
inhibits inducible nitric oxide synthase (iNOS) and platelets 
aggregation, elevates high-density lipoprotein, and reduces 
low-density lipoprotein, trigycerides, and reactive oxygen 
species (ROS) accumulation (5). Resveratrol acts against the 
oxidative stress via the up-regulation of antioxidant enzymes 
synthesis and enhancement of the anti-oxidant capacity, free 
radical scavenging activity, as well as the inhibition of lipid 
because of its complexity and multi-factorial nature, has 
remained as a challenging medical problem (7). Resveratrol 
by inhibition of the adipogenesis and down-regulation of 
lipogenic genes, and enhancement of fat oxidation has shown 
promising anti-obesity effects (8). In type 2 diabetes mellitus, 
resveratrol, by activating sirtuin 1, elevates the glucose uptake 
Regarding the neuroprotective properties of resveratrol, 
there are reports indicating its inhibitory effects against the 
in the hippocampus. Resveratrol improves the sensorimotor 
function, modulates the cholinergic neurotransmission, and 
prevents the oxidative damage of astroglial cells and cognitive 
decline. This natural compound downregulates the glutamate-
induced extracellular signal-regulated kinase activation and 
interleukin-1
Study on the primary cortical neuron cultures has revealed 
that resveratrol through the inhibition of intracellular calcium 
increase and production of ROS exerts the protective effect 
against N-Methyl-D-aspartate-induced neuronal death (13). 
Furthermore, this natural polyphenol by antioxidant activities 
protects the hippocampal neurons against the NO-induced 
toxicity (14). In Alzheimer’s disease, resveratrol has been 
shown to  NO 
production, iNOS expression, prostaglandin E2 accumulation, 
and NF- B translocation (15). Resveratrol exhibits therapeutic 
potential in other neurodegenerative diseases such as 
Parkinson’s disease (16) and amyotrophic lateral sclerosis 
properties. This polyphenolic compound prevents the spinal 
cord and brain damage following the ischemia-reperfusion or 
traumatic injury (18).
In recent years, it has been shown that resveratrol exerts 
antidepressant effects via the modulation of hypothalamic-
pituitary (HPA) axis activity and oxidative-nitrosative stress 
(19-21). Based on an increasing evidence, neurotrophins, 
a protein family including the nerve growth factor (NGF), 
brain-derived neurotrophic fac tor (BDNF), neurotrophin 3 
(NT-3), NT-4/5, and NT-6 act as the potential mediators of 
antidepressant responses (22, 23). Neurotrophins mediate 
their effects by the ligation of two major types of receptors: a 
pan-neurotrophin receptor (p75N TR), thus trigger a number of 
cel lular responses including the long-term trophic effects as 
well as the rapid chemo tropic and morphogenetic actions on 
the developing neurons, synaptic transmission, and neuronal 
excitability (24-27). Neurotrophins  are also implicated in the 
neuronal plasticity and exhibit neuroprotective effects that 
disorders (28). Indeed, dysfunction of the neurotrophin-related 
signalling mechanisms is involved in the pathogenesis of a 
number of psychiatric disorders (23-26). The prototypical 
neurotrophin, NGF, which regulates the stress and cognitive 
function (29,30) and mediates the action of a wide variety 
of psychotropic agents (31-35), along with the eCBs which 
regulates the neuroprotective processes (36), are implicated 
in the mechanism of action of resveratrol (37) that will be 
discussed herein.
RESEVERATROL AND NGF
Following the discovery of the first neurotrophin, NGF, 
by the Nobel Laureate Rita Levi-Montalcini (38), further 
Figure 1. The chemical structure of resveratrol.
15
Biomed Rev 26, 2015
Resveratrol, NGF, and endocannabinoids
studies showed that NGF as well as other neurotrophins 
(e.g. BDNF) affect the neuronal survival and differentiation, 
exerts a regulatory role in the memory and attention tasks, 
in neuroendocrine-immune interaction, and neurological 
disorders (39, 41). Be cause of its antioxidant, angiogenic and 
metabotrophic (including insulinotropic) prop erties, NGF is 
implicated in the molecular mechanisms of cardiometabolic 
diseases (41, 42, 48 and references therein), accelerates corneal 
and skin wound healing (43, 44) and plays a fundamental role 
in tissue engineering (45). Over the last decade, it has been 
suggested that electroconvulsive treatment or antidepressant 
drugs may act by increasing neurotrophin contents in the 
cen tral nervous system (CNS). Based on the ability of NGF 
to induce the release of hypothalamic vasopressin which 
plays a crucial role in the formation of social bonding (46), it 
was suggested that NGF by modulating the neuroendocrine 
functions is implicated in the molecular mechanisms of 
emotions. In this respect, the involvement of NGF and 
BDNF in the pathogenesis of neuropsychiatric disorders 
(39, 41, 47-49) and in the mechanisms of action of a wide 
range of psychotropic agents (31-35, 41, 50) were reported. 
management of neuropsychiatric disorders. Recently, the 
involvement of NGF in the mech anism of action of resveratrol 
has also been reported (37). The elevation of brain NGF 
levels following chronic treatment with resveratrol indicates 
that the neurotrophic effect is a slow-developing process. 
The sustained enhancement of NGF protein contents in the 
brain regions which regulate the emotional activity may be 
considered as a mechanism by which resveratrol exerts its 
therapeutic effects in the neuropsychiatric disorders. Since 
NGF exerts the stimulatory effect on the cell proliferation (51), 
therefore, the elevation of frontal cortex NGF following the 
chronic administration of resveratrol might be of therapeutic 
significance against the stress-induced reduction in cell 
proliferation in the frontal cortex (52).  
Resveratrol also elevates NGF level in the hippocampus 
(37). It is noteworthy that NGF plays a pivotal role in learning, 
hippocampal plasticity, and neurogenesis (29, 30), and induces 
acetylcholine release in the hippocampus (49) leading to the 
improved cognitive performance. Therefore, resveratrol by 
enhancement of the hippocampal NGF may stimulate the 
hippocampal neurogenesis and improve the cognitive function. 
Moreover, this nutraceutical increases NGF contents in the 
olfactory bulb and amygdala (37). The critical role of NGF 
in the development, regeneration, and mainte nance of the 
olfactory system of mammals has been well-documented (29, 
30, 53). NGF also facilitates the cholinergic neurotransmis sion 
between the amygdala and nucleus basalis (54) leading to 
the improvement of cognitive function. Altogether, it appears 
that elevation of brain NGF, also BDNF, contents constitutes 
a major part of the biochemical altera tions induced by certain 
psychotropic agents (31-35, 41, 50) including resveratrol (37).
RESVERATROL AND THE ENDOCANNABINOID SIGNALING
Over the last decade, the eCBs, a group of neuromodu-
latory lipids and their receptors which regulates the neuronal 
proliferation and maturation (55), synaptic plasticity (56), 
emotional reactivity (57), neurotensin neurotransmission 
(58-59) and neurotrophin signalling (60, 61), has emerged as 
a topic of great interest in neuroscience and pharmacology. The 
endocan nabinoids, anandamide and 2-ara chidonoylglycerol 
(2-AG), are produced on-demand by the lipid precursors 
in the neuronal cell membrane and activate two types of 
G protein-coupled receptors, cannabinoid CB1 and CB2, 
leading to a wide variety of pathological and physiological 
processes. The eCBs exerts neuroremodulatory action in 
various types of diseases (62). In this context, development of 
anandamide uptake blockers, cannabinoid receptor agonists, 
and selective inhibitors of endocannabinoid degradation has 
been the focus of intense research (63, 64). In transsynaptic 
neuronal changes due to the neurodegenerative processes (65), 
microglia-induced neurotoxicity, and cytotoxicity induced by 
the excitatory amino acids (66), the eCBs exerts protective 
effects (67). In general, the endocannabinoids exert their 
neuroprotective effects through a variety of mechanisms 
and/or glutamate release, and activation of antioxidative 
mechanisms. Furthermore, activation of the CB1 receptors 
leads to the stimulation of phosphoinositide 3-kinase (PI3-K)/
AKT signalling pathway and promotion of the cell survival 
(68). According to the protective effects of the eCBs against 
the excitotoxic damage and neuronal insult (58, 67), this 
ubiquitous signalling system might be an emerging target 
for the therapeutic interventions against the neurological 
disorders. In Parkinson’s disease (PD), the most prevalent 
neurodegenerative disorder affecting the basal ganglia, 
dopamine depletion results in a cascade of neurochemical 
events within the basal ganglia. Endocannabinoids and 
their synthesizing and degrading enzymes are abundantly 
found in the basal ganglia (69). Indeed, the striatal eCBs 
undergoes a profound neurophysiological alteration in order 
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to restore the homeostasis within the basal ganglia (70). In 
Huntington’s disease, the CB1 receptor agonists and inhibitors 
of eCB transport reduce the hyperkinesia associated with 
the disease (71). Stimulation of the CB1 or CB2 receptors 
in multiple sclerosis 
(72). Furthermore, CB1 agonists promote the oligodendro-
cyte survival and mRNA expression of myelin protein (73) 
suggesting that the eCBs not only attenuates the symptoms of 
the disease, but also improves the function of oligodendrocytes 
effects. In the spinal cord injury, a cascade of cellular and 
molecular events which occur following the initial damage, 
is a main target for therapeutic interventions including the 
application of cannabinoids. In an animal model of the spinal 
cord injury, 
reported (74) suggesting that activation of the eCBs is a part 
of the neuroprotective response which is triggered following 
the injury. 
In epilepsy, the imbalance between the inhibitory and 
excitatory neural circuits leads to the excitotoxicity and 
neuronal death (75-77). Based on the regulatory effects of 
the eCBs on the inhibitory and excitatory transmissions and 
the enhancement of the eCB contents in epilepsy (78), this 
ubiquitous signalling system may be a promising target for 
antiepileptic therapies. In ischemic stroke, recombinant tissue 
plasminogen activator improves the functional outcome in 
patients, however, it should be administered within a short 
period of time following the onset of symptoms. The non-
psychoactive component of cannabis, cannabidiol, has been 
shown to inhibit the voltage-sensitive Ca2+ channels leading to 
the reduction of excitotoxicity. Administration of cannabidiol 
6 h after the cerebral ischemia has led to the neuroprotective 
effects. Furthermore, cannabidiol has preserved the regional 
at 3 days after the cerebral ischemia (79) indicating its long-
lasting preventive effects on the post-ischemic cerebrovascular 
events.
In Alzheimer’s disease which is associated with neuro-
-
(62, 81).
may exert protective effects through the inhibition of NO 
release and activation of mitogen-activated protein kinase 
pathway (82). 
In amyotrophic lateral sclerosis, one of most the debilitating 
neurodegenerative disorder which is characterised by the 
degeneration of motor neurons, the eCBs has shown anti-
excitotoxic damage and preservation of glutamate homeostasis 
(83). Following the  of the endocannabinoid 
binding sites in substan tia gelatinosa,  analgesic effects 
of the eCBs in both acute and chronic pain
(84, 85). The interaction between the opioid signalling and 
eCBs is also well-documented (86). Based on these multi-
target bioactivities of the eCBs, its potential implication in 
the mechanism through which resveratrol regulates brain 
NGF contents has been investigated. It has been found that 
resveratrol affects brain NGF levels under the regulatory drive 
of CB1 receptors (37). Furthermore, the brain eCB contents 
are increased following the chronic treatment with resveratrol 
(37). It appears that the eCBs activation is required, at least in 
part, for the neuroprotective actions of resveratrol against the 
various types of neurological disorders. 
Regarding the mood disorders, compounds which affect the 
eCBs function have been shown to regulate the monoamine-
mediated neurotransmission and activity of HPA axis (87). In 
the limbic brain regions where the neuronal activity is altered 
in depression (88), endocannabinoids are found at moderate 
to high levels (87). Indeed, the regulatory role of the eCB 
enhancers on mood (57), has opened a new line of research 
in antide pressant drug discovery and development of novel 
anxiety-related disorders as the CB1 receptor antagonist, 
SR141716A, has been shown to induce anxiety-like responses 
(89). Chronic exposure to a wide range of psychotropic agents 
the brain regions which regulate the synaptic plasticity and 
emotional behaviour (32-35, 37). In fact, the brain regional 
distribu tion of endocannabinoids following the administration 
of psychotropic agents represents the important role of the 
eCBs in the development of effective coping strategies to the 
emotional responses. As recently reported, four-week once-
daily injections of resveratrol results in a sustained elevation 
of annadamide and 2-AG contents in the brain regions 
implicated in the modulation of emotional behaviour and 
an intrinsic eCB tone which is involved in the mechanism of 
action of resveratrol. 
Following chronic administration of resveratrol, NGF 
and endocannabinoids have been increased in the same brain 
regions suggesting that the regulatory effect of resveratrol 
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on brain NGF contents depends on the coordinated release 
of endocannabinoids. It appears that a balance between NGF 
and eCB signalling mediates the pharmacological effects of 
this natural polypheonlic compound. In addition to its intrinsic 
radical scavenging activity, resveratrol reduces the production 
expression of iNOS gene. This natural polyphenol upregulates 
the activities of protein kinase C and heme oxygenase leading 
to the neuroprotective effects. In fact, multiple intracellular 
signalling pathways and molecular targets are involved in the 
mechanism of action of resveratrol (90). Involvement of the 
extracellular signal-regulated kinase cascade, noradrenaline 
and serotonin system, and HPA axis in the antidepressant-
like effects of resveratrol has been previously demonstrated 
eCBs are also implicated in the mechanism of action of 
resveratrol. In this context, resveratrol by affecting NGF and 
of diseases which are associated with abnormal NGF or 
eCBs. Resveratrol enhances the brain NGF contents under the 
regulatory drive of CB1 receptors indicating the importance of 
the endogenous cannabinoid activity in the neurotrphic action 
of this nutraceutical. 
In recent years, smart delivery of drugs, neurotrophins, 
and nutrients has been the focus of intense research. In 
nanotechnology-based approaches, nanoencapsulation of 
nutraceuticals, application of nanosensors and computational 
modelling have been the emerging topics (93-97). In this 
respect, designing the nanoformulations of resveratrol has led 
to the increased cellular uptake and improved bioavailability 
potential side effects of this nutraceutical which has shown 
multi-spectrum therapeutic applications.
CONCLUSION 
For over a decade, natural products with antioxidant, 
antiinflammatory, metabotrophic and neuroptotective 
effects have been the focus of intense research. Resveratrol, 
a naturally occurring polyphenolic compound, has shown 
multi-spectrum therapeutic applications. Besides its 
therapeutic potential in ischemia, cancer, diabetes, and 
cardiometabolic disorders, resveratrol has proved to be a 
promising therapeutic agent against the neurodegenerative 
disorders. In recent years,
functions of the eCBs has resulted in a better understanding 
of the pathological processes which occur in the CNS. 
Compounds which regulate the activity of the eCBs, have 
against various disorders in which 
 
The eCBs as the modulator of the neurodegenerative and 
the pharmacotherapy of chronic CNS disorders. Resveratrol 
by affecting the eCBs and NGF with well-documented 
regulatory actions in the neuroprotective processes and 
emotional activity might be a valuable therapeutic agent 
against a wide variety of disorders associated with abnormal 
eCB or NGF signalling.
interest.
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